UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Nkarta, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
65487U 108
(CUSIP Number)
| Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592
Copy to:
B. Shayne Kennedy, Esq. Latham & Watkins LLP 650 Town Center Drive, 20th Floor Costa Mesa, CA 92626 Telephone: (714) 540-1235 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
May 12, 2022
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No.: 65487U 108
| 1. | Name of Reporting Person:
Novo Holdings A/S | |||||
| 2. | Check the Appropriate Box if a Member of Group (See Instructions): (a) ☐ (b) ☐
| |||||
| 3. | SEC Use Only:
| |||||
| 4. | Source of Funds:
WC | |||||
| 5. | Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):
☐ | |||||
| 6. | Citizenship or Place of Organization:
Denmark | |||||
| Number of Shares Beneficially Owned By Each Reporting Person With:
|
7. | Sole Voting Power:
2,238,309 | ||||
| 8. | Shared Voting Power:
0 | |||||
| 9. | Sole Dispositive Power:
2,238,309 | |||||
| 10. | Shared Dispositive Power:
0 | |||||
| 11. |
Aggregate Amount Beneficially Owned by Each Reporting Person:
2,238,309 | |||||
| 12. | Check if the Aggregate Amount in Row (11) Excludes Certain Shares:
☐ | |||||
| 13. | Percent of Class Represented By Amount In Row (11):
4.6% (1) | |||||
| 14. | Type of Reporting Person:
CO | |||||
| (1) | Based upon 48,404,331 shares of the Issuer’s Common Stock outstanding as of May 9, 2022, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on May 12, 2022. |
2
| Item 1. | Security and Issuer |
Item 1 is amended and replaced in its entirety as follows:
This amendment (“Amendment No. 3”) amends the Schedule 13D originally filed with the SEC on July 14, 2020, as subsequently amended by Amendment No. 1 filed on November 8, 2021 and Amendment No. 2 filed May 2, 2022 (collectively, the “Schedule”), to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Stock due to an increase in the outstanding shares of Common Stock of the Issuer. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.
| Item 5. | Interest in Securities of the Issuer |
Item 5 amends and supplements Item 5 in the Schedule as follows:
| (a) | Novo Holdings A/S beneficially owns 2,238,309 shares of Common Stock (the “Novo Shares”) representing approximately 4.6% of the Issuer’s outstanding shares of Common Stock, based upon 48,404,331 shares of the Issuer’s Common Stock outstanding as of May 9, 2022, as reported in the Issuer’s Form 10-Q filed with the SEC on May 12, 2022. |
| (b) | Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. |
| (c) | Since the Schedule 13D/A filed on May 2, 2022, Novo Holdings A/S has not effected any transactions in the shares of the Issuer’s Common Stock and neither the Foundation nor any person listed on the Schedule I has effected any transactions in the Issuer’s Common Stock. The information set forth in Item 3 of the Schedule 13D/A filed on May 2, 2022 is incorporated herein. |
| (d) | Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. |
| (e) | As of May 12 2022, Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Stock. |
3
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: June 3, 2022 | Novo Holdings A/S | |||||
| /s/ Barbara Fiorini Due | ||||||
| By: Barbara Fiorini Due Its: General Counsel, Finance & Operations | ||||||
4